These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3753579)

  • 1. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.
    Stratford IJ; O'Neill P; Sheldon PW; Silver AR; Walling JM; Adams GE
    Biochem Pharmacol; 1986 Jan; 35(1):105-9. PubMed ID: 3753579
    [No Abstract]   [Full Text] [Related]  

  • 2. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ; Walling JM; Silver AR
    Br J Cancer; 1986 Mar; 53(3):339-44. PubMed ID: 3754453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
    Ahmed I; Jenkins TC; Walling JM; Stratford IJ; Sheldon PW; Adams GE; Fielden EM
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ; Sapora O; O'Neill P; Fielden EM
    Biochem Pharmacol; 1988 Oct; 37(20):3837-42. PubMed ID: 3190731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole.
    Born JL; Smith BR; Harper N; Koch CJ
    Biochem Pharmacol; 1992 Mar; 43(6):1337-44. PubMed ID: 1562284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mutations in V79-4 mammalian cells under hypoxic and aerobic conditions by the cytotoxic 2-nitroimidazole-aziridines, RSU-1069 and RSU-1131. The influence of cellular glutathione.
    Sapora O; Paone A; Maggi A; Jenner TJ; O'Neill P
    Biochem Pharmacol; 1992 Oct; 44(7):1341-7. PubMed ID: 1417957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
    Walling JM; Stratford IJ; Adams GE; Silver AR; Ahmed I; Jenkins TC; Fielden EM
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1083-6. PubMed ID: 3755712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of DNA strand breaks by RSU-1069, a nitroimidazole-aziridine radiosensitizer. Role of binding of both unreduced and radiation-reduced forms to DNA, in vitro.
    Silver AR; O'Neill P; Jenkins TC
    Biochem Pharmacol; 1985 Oct; 34(19):3537-42. PubMed ID: 3902026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative DNA damage induced by nitroimidazole-aziridine drugs: 1. Effects of methyl substitution on drug action.
    Dale LD; Tocher JH; Edwards DI
    Anticancer Drug Des; 1988 Dec; 3(3):169-75. PubMed ID: 3207464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the toxicity of RSU-1069.
    Whitmore GF; Gulyas S
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1219-22. PubMed ID: 3755716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The repair of DNA damage induced in V79 mammalian cells by the nitroimidazole-aziridine, RSU-1069. Implications for radiosensitization.
    Jenner TJ; O'Neill P; Crump PW; Fielden EM; Sapora O; Santodonato L
    Biochem Pharmacol; 1991 Oct; 42(9):1705-10. PubMed ID: 1930296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging.
    Biskupiak JE; Grierson JR; Rasey JS; Martin GV; Krohn KA
    J Med Chem; 1991 Jul; 34(7):2165-8. PubMed ID: 2066990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine.
    O'Neill P; Cunniffe SM
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):963-6. PubMed ID: 2649467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
    Adams GE; Ahmed I; Sheldon PW; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
    Hei TK; Geard CR; Osmak RS; Hall EJ
    Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metabolite of the 2-nitroimidazole misonidazole with radiosensitizing properties.
    Flockhart IR; Sheldon PW; Stratford IJ; Watts ME
    Int J Radiat Biol Relat Stud Phys Chem Med; 1978 Jul; 34(1):91-4. PubMed ID: 309446
    [No Abstract]   [Full Text] [Related]  

  • 17. Newly synthesized hypoxia-mediated drugs as radiosensitizers and cytotoxic agents.
    Astor M; Hall EJ; Biaglow JE; Parham JC
    Int J Radiat Oncol Biol Phys; 1982 Jan; 8(1):75-83. PubMed ID: 7061257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation of the radiosensitizing efficiency of RSU-1069 with pre-irradiation contact times: a rapid mix study.
    Austen KR; Jenner TJ; O'Neill P; Fielden EM
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Aug; 52(2):281-8. PubMed ID: 3497125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ; Hei TK
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI; Workman P
    Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.